Rapid Genomic Medicine Advances Will Reshape The Diagnostics Landscape
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 3 Analysts
Published
10 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$30.00
28.3% undervalued intrinsic discount16 Aug
US$21.52
1Y
-9.6%7D
4.4%